Merck KGaA, Darmstadt, Germany, Named One of the Global Top Employers in 2018

Merck KGaA, Darmstadt, Germany announced today it has been named one of only 13 global employers of choice by the Top Employers Institute.

16 Feb 2018 | Darmstadt, Germany
  • Merck KGaA, Darmstadt, Germany, was also certified as a Top Employer in the areas Asia/Pacific, Middle East, Europe as well as North and Latin America
  • National certifications also received in 24 countries
  • Top Employers Institute honors leading employers worldwide

Darmstadt, February 16, 2018 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced today it has been named one of only 13 global employers of choice by the Top Employers Institute. The independent research shows Merck KGaA, Darmstadt, Germany, stands out as an exceptional employer with regard to talent development, performance management, and career and succession planning. In addition to the “Global Top Employer 2018” certification, the Group was also named “Top Employer Europe 2018,” as well as “Top Employer Germany 2018.”

“Throughout our 350-year history, attracting the best and brightest talent around the globe has been a fundamental part of what we do as a successful company,” said Belén Garijo, CEO Healthcare and Member of the Executive Board in charge of Corporate HR at Merck KGaA, Darmstadt, Germany. “This recognition reaffirms the potential for people joining and growing within our organization; the opportunities are boundless.”

The annual international research undertaken by the Top Employers Institute recognizes leading employers around the world through a stringent research process in which they are assessed on criteria including talent strategy, performance management, leadership development and culture. This includes HR best practice surveys that determine which companies have reached the required standards to create optimal conditions for their employees to develop, both professionally and personally and therefore, be certified as Top Employers.

Besides the recognition in Europe, Merck KGaA, Darmstadt, Germany, also received regional certifications in Asia/Pacific, the Middle East, Latin America as well as for its North America businesses for 2018. In addition, the Group was also ranked number 4 among the top 20 employers in the global biopharmaceutical industry by Science magazine, a leading peer-reviewed international scientific publication, in 2017.

To know more about the Top Employer Institute and its certifications, visit:


For more information, please contact Markus Talanow

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.


Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck KGaA, Darmstadt, Germany, name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Related News

  1. Press Releases

    Merck KGaA, Darmstadt, Germany, to Showcase Advances in the Science of Cancer

    Merck KGaA, Darmstadt, Germany, today announced new research from the company’s diverse oncology portfolio will be presented at ASCO 2024.